Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11073984 | 0.93 | LMNA (0.60) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL28141267 | 0.90 | LMNA (0.53) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL30701898 | 0.83 | MAOB (0.51) | MAOBMAOABCHENR4A2ALOX5 | |
| SCHEMBL17187134 | 0.83 | MAOB (0.51) | MAOBMAOABCHENR4A2ALOX5 | |
| Boric Acid SCHEMBL3219236 | 0.83 | CYP1A2 (0.53) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Benzylphenylether SCHEMBL18549916 | 0.82 | LMNA (0.63) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Acetamide SCHEMBL3217821 | 0.81 | MAOB (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Trifluoromethanesulfonic Acid SCHEMBL11066760 | 0.81 | PTPRZ1 (0.51) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL6801696 | 0.78 | MRGPRX4 (0.54) | MAOBMAOARAB9AALOX5CA12 | |
| SCHEMBL339813 | 0.78 | LMNA (0.82) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041876-A1 | PROCESS FOR PREPARING AROMATIC DIAZONIUM SALTS | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2010-02-18 | — | — | US | claimed |
| CN-118005593-A | Preparation method of 2, 3-disubstituted chromone compound | 昆明理工大学 | 2024-05-10 | — | — | CN | disclosed |
| US-20130053598-A1 | METHOD FOR PRODUCING A CROSS-COUPLING PRODUCT OF A BENZENOID DIAZONIUM SALT | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2013-02-28 | — | — | US | disclosed |
| EP-2421822-A1 | METHOD FOR PRODUCING A CROSS-COUPLING PRODUCT OF A BENZENOID DIAZONIUM SALT | Zylum Beteiligungsgesellschaft mbH & Co. Patente II KG (DE) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122105-A1 | METHOD FOR PRODUCING A CROSS-COUPLING PRODUCT OF A BENZENOID DIAZONIUM SALT | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2010-10-28 | — | — | WO | disclosed |
| EP-2243768-A1 | Phenolic diazonium salt, method for its production and its application | Zylum Beteiligungsgesellschaft mbH & Co. Patente II KG (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100041876-A1 | PROCESS FOR PREPARING AROMATIC DIAZONIUM SALTS | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2010-02-18 | — | — | US | disclosed |
| EP-1034164-B1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-6645939-B1 | Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-6420418-B1 | INHIBITION AND PREVENTION OF LEUKOCYTE ADHESION; USED TO TREAT ADHESION-MEDIATED DISEASES SUCH AS ASTHMA, ALLERGIC RHINITIS, MULTIPLE SCLEROSIS; ATHEROSCLEROSIS, AND INFLAMMATORY BOWEL DISEASE | MERCK & CO., INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1034164-A4 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2001-07-11 | — | — | EP | disclosed |
| WO-2001012183-A1 | HETEROCYCLE AMIDES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| EP-1034164-A1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-1999026921-A1 | SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041876-A1 | PROCESS FOR PREPARING AROMATIC DIAZONIUM SALTS | AHNAK, NAT1, HNMT | LMNA 3176/4885CYP1A2 362/4885PTGS1 3220/4885 |
| US-20130053598-A1 | METHOD FOR PRODUCING A CROSS-COUPLING PRODUCT OF A BENZENOID DIAZONIUM SALT | CBR3, CBR1, NOX3 | LMNA 2854/4885CYP1A2 1689/4885PTGS1 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.